Simlukafusp alfa (Simridarlimab) is a humanized bispecific antibody targeting both PD-L1 and CD47. It is used in research to investigate dual checkpoint blockade, with applications in immuno-oncology for in vitro cell-based assays and in vivo tumor model studies.